October 28, 2024 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today announced that it has entered into a global distribution partnership with Beckman Coulter, Inc., a global clinical diagnostics leader. Beckman Coulter will distribute BioPorto’s neutrophil gelatinase-associated lipocalin (NGAL) tests for use on Beckman Coulter family of DxC and AU clinical chemistry analyzers.